Experimental skin cream shows 2-year biological age reduction in early trial

A biotechnology company in Mountain View has released preliminary data from an early human trial of an experimental skin cream that appears to slow the molecular clock of aging skin. Rubedo Life Sciences tested RLS-1496, its investigational treatment, on a small group of patients with eczema and other skin conditions. The results, presented at a scientific conference but not yet published in a peer-reviewed journal, suggest the cream may work at the cellular level rather than simply masking wrinkles.

In the most striking finding, researchers analyzed skin samples from eleven patients with atopic dermatitis after four weeks of treatment. The epigenetic markers they measured—age-related changes in DNA that serve as a biological clock for skin—showed an average decrease of 2.1 years. Alongside this, the treated skin showed a 10% increase in a type of collagen that provides structural support. Blood tests also revealed lower levels of several inflammatory markers, though researchers have not yet determined what these changes mean for patients' actual health or appearance.

The drug works by targeting senescent cells, which are aging or damaged cells that have stopped dividing but continue to release inflammatory substances. RLS-1496 focuses on a protein called GPX4, which helps cells respond to stress. The theory is that blocking this protein clears away damaged, aging cells while allowing healthier cells to survive and strengthen. Rubedo CEO Dr. Frederick Beddingfield framed the approach as addressing cellular aging itself rather than its surface symptoms. "It's a bit like 'what does not kill you makes you stronger' for those surviving cells," he said, describing how the treatment might work at the fundamental level.

The early results come with significant caveats. The skin-aging analysis involved only eleven paired samples, a very small number for drawing broad conclusions. The trial lasted just four weeks, leaving open the question of whether the measured changes persist over time or fade once treatment stops. The study was sponsored by Rubedo itself, and the findings have not undergone independent peer review. The skin samples showed biological markers of reduced aging, but the trial did not measure whether skin actually looked younger or functioned better in any observable way.

Rubedo is pursuing the treatment across multiple skin conditions. In a separate early-stage study of twenty-two patients with actinic keratosis—rough, precancerous patches caused by sun exposure—the company reported a 49% average reduction in lesions after twenty-eight days of treatment. That study compared treated forearms to untreated forearms on the same patients rather than using a placebo control. The cream caused minimal skin irritation, and very few participants showed detectable levels of the drug in their bloodstream after topical application, suggesting the treatment works locally on the skin rather than entering the body systemically.

Beddingfield acknowledged the limitations and outlined the path forward. The company's next trial will extend treatment for several months rather than four weeks, addressing one of the key unknowns about whether the changes are durable. Rubedo is also beginning early-stage testing of RLS-1496 for androgenetic alopecia, or pattern hair loss, expanding the potential applications. The CEO estimated that FDA approval remains three to four years away, contingent on the results of larger clinical trials. For now, the cream remains experimental, and the question of whether these early molecular changes translate into visible, lasting improvements in skin aging remains unanswered.